TMS for Exposure Therapy Resistant OCD

Recruiting Phase 3 Interventional Study
1 Hz Real rTMS to the Pre-SMA 1 Hz Sham rTMS to the Pre-SMA
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
250 (estimated)
Sponsor
Amsterdam UMC, location VUmc · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
TETRO is a multi-center placebo-controlled double-blind randomized controlled trial with an intervention phase of 5-7 weeks and a follow-up phase of 12 months in 250 adult (18 years and older) OCD patients who show no/insufficient response to ERP, aiming to establish the cost-effectiveness of low frequency (1 Hz) rTMS to the pre-SMA (compared to sham rTMS to the pre-SMA) as adjuvant treatment to e…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * OCD as current primary diagnosis * Age 18 and older * Yale-Brown Obsessive-Compulsive Scale (YBOCS) score of 16 or higher. * Insufficient response to state-of-the art exposure therapy with response prevention (ERP) and/or drop-out from ERP due to extreme anxiety/avoidance * Th…
Contacts

Odile A van den Heuvel, MD PhD

+31-20-4444444

oa.vandenheuvel@amsterdamumc.nl

CONTACT

Tjardo S Postma, MD

+31-20-4444444

tetro@amsterdamumc.nl

CONTACT